Medigene strengthens its DC platform with patent for treatment of stem cell or bone-marrow transplanted patients – Nasdaq
|
Medigene strengthens its DC platform with patent for treatment of stem cell or bone-marrow transplanted patients
Nasdaq For a stem cell or bone-marrow donation without an available HLA-identical "sibling", healthy relatives of the patient are considered meanwhile as the best potential donors. Those donors are at least HLA haplo-identical with respect to the patient … |
